Enclomiphene vs Halotestin
Well Studied vs Well Studied
avoid Mechanism-based · 64% Both Enclomiphene and Halotestin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Enclomiphene Halotestin
Weight 405.96 Da 336.44 Da
Half-life ~10 hours ~9.5 hours
Type Trans-isomer of clomifene (selective estrogen receptor modulator) 9-fluoro-11-beta-hydroxy-17-alpha-methyltestosterone (C20H29FO3)
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Halotestin
01 Dramatic increase in strength and power output without water retention
02 Pronounced increase in aggression and competitive drive
03 Does not aromatize to estrogen, producing a hard and dry appearance
04 Enhances red blood cell production and oxygen-carrying capacity
05 Rapid onset of effects, typically noticeable within days
06 Uniquely suited for pre-competition or pre-meet peaking protocols
07 Short cycle duration limits cumulative exposure
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Halotestin
Severe hepatic stress (elevated ALT, AST, GGT, bilirubin)
Pronounced aggression and irritability
HDL cholesterol suppression and LDL elevation
Elevated blood pressure
Headaches (frequently reported, may be related to blood pressure changes)
Suppression of endogenous testosterone production
Oily skin and acne
Decreased appetite (potentially related to liver stress)
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Known or suspected prostate cancer
Breast cancer in males
Pregnancy (Category X - causes fetal harm)
Active liver disease or existing hepatic impairment
Severe cardiovascular disease or uncontrolled hypertension
Hypercalcemia
Nephrosis or nephrotic phase of nephritis
History of cholestatic jaundice or hepatic dysfunction from prior anabolic steroid use
Hypersensitivity to fluoxymesterone or any formulation component
Research Evidence
Enclomiphene Halotestin
Status Well Studied Well Studied
References 5 studies 5 studies
Latest — October 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.